Cargando…

Master protocols: New directions in drug discovery

A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more tha...

Descripción completa

Detalles Bibliográficos
Autor principal: Bogin, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205752/
https://www.ncbi.nlm.nih.gov/pubmed/32395664
http://dx.doi.org/10.1016/j.conctc.2020.100568
_version_ 1783530298180370432
author Bogin, Vladimir
author_facet Bogin, Vladimir
author_sort Bogin, Vladimir
collection PubMed
description A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure. The ability to use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, speeds up drug development and makes it more efficient. Thus, it is important for the clinical trial professionals to understand both the basic principles of master protocol trials and the way innovative trial designs are starting to change the landscape of clinical research.
format Online
Article
Text
id pubmed-7205752
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72057522020-05-11 Master protocols: New directions in drug discovery Bogin, Vladimir Contemp Clin Trials Commun Article A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure. The ability to use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, speeds up drug development and makes it more efficient. Thus, it is important for the clinical trial professionals to understand both the basic principles of master protocol trials and the way innovative trial designs are starting to change the landscape of clinical research. Elsevier 2020-04-25 /pmc/articles/PMC7205752/ /pubmed/32395664 http://dx.doi.org/10.1016/j.conctc.2020.100568 Text en © 2020 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Bogin, Vladimir
Master protocols: New directions in drug discovery
title Master protocols: New directions in drug discovery
title_full Master protocols: New directions in drug discovery
title_fullStr Master protocols: New directions in drug discovery
title_full_unstemmed Master protocols: New directions in drug discovery
title_short Master protocols: New directions in drug discovery
title_sort master protocols: new directions in drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205752/
https://www.ncbi.nlm.nih.gov/pubmed/32395664
http://dx.doi.org/10.1016/j.conctc.2020.100568
work_keys_str_mv AT boginvladimir masterprotocolsnewdirectionsindrugdiscovery